Reports
Reports
Sale
The bladder cancer treatment market growth is expected to be influenced by unhealthy lifestyles, such as bladder infections, genetic abnormalities, smoking, and chemical exposure. The bladder cancer treatment market is further expected to grow due to improvements in cancer treatment methods.
The market growth is predicted to be driven by an aging population as well. Increased treatment costs will further limit the growth of the market over the long term. Moreover, emerging markets offer opportunities for market growth. The bladder cancer therapy market, however, may be further hampered by post-treatment side effects.
Bladder Cancer Treatment Market Size
Bladder Cancer Treatment Market Growth
Bladder Cancer Treatment Companies
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.1.1 Research Objectives
1.1.2 Key Findings of the Report
1.2 Limitations of the Study and Scope for Future Research
2 Research Methodology
3 Executive Summary
4 Global Bladder Cancer Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Global Bladder Cancer Treatment Market
6.1 Global Bladder Cancer Treatment Market Overview
6.2 Global Bladder Cancer Treatment Market Analysis
6.2.1 Market Overview
6.2.1.1 Global Bladder Cancer Treatment Market Historical Value (2017-2023)
6.2.1.2 Global Bladder Cancer Treatment Market Forecast Value (2024-2032)
6.2.2 Global Bladder Cancer Treatment Market by Type
6.2.2.1 Market Overview
6.2.2.1.1 Invasive Bladder Cancer
6.2.2.1.1.1 Non-Muscle-Invasive Bladder Cancer
6.2.2.1.1.2 Muscle-Invasive Bladder Cancer
6.2.2.1.2 Transitional Bladder Cancer
6.2.2.1.3 Squamous Cell Bladder Cancer
6.2.2.1.4 Others
6.2.3 Global Bladder Cancer Treatment Market by Diagnosis Method
6.2.3.1 Market Overview
6.2.3.1.1 Cystoscopy
6.2.3.1.2 Biopsy
6.2.3.1.3 Urine Cytology
6.2.3.1.4 Imaging Tests
6.2.4 Global Bladder Cancer Treatment Market by Treatment Method
6.2.4.1 Market Overview
6.2.4.1.1 Surgery
6.2.4.1.2 Intravesical Chemotherapy
6.2.4.1.3 Systemic Chemotherapy
6.2.4.1.4 Radiation Therapy
6.2.4.1.5 Immunotherapy
6.2.4.1.6 Targeted Therapy
6.2.5 Global Bladder Cancer Treatment Market by Treatment Channel
6.2.5.1 Market Overview
6.2.5.1.1 Public
6.2.5.1.2 Private
6.2.6 Global Bladder Cancer Treatment Market by Region
6.2.6.1 Market Overview
6.2.6.1.1 North America
6.2.6.1.2 Europe
6.2.6.1.3 Asia Pacific
6.2.6.1.4 Latin America
6.2.6.1.5 Middle East and Africa
6.2.6.2 North America
6.2.6.2.1 Historical Trend (2017-2023)
6.2.6.2.2 Forecast Trend (2024-2032)
6.2.6.2.3 Break Up by Country
6.2.6.2.3.1 United States of America
6.2.6.2.3.2 Canada
6.2.6.3 Europe
6.2.6.3.1 Historical Trend (2017-2023)
6.2.6.3.2 Forecast Trend (2024-2032)
6.2.6.3.3 Break Up by Country
6.2.6.3.3.1 United Kingdom
6.2.6.3.3.2 Germany
6.2.6.3.3.3 France
6.2.6.3.3.4 Italy
6.2.6.3.3.5 Others
6.2.6.4 Asia Pacific
6.2.6.4.1 Historical Trend (2017-2023)
6.2.6.4.2 Forecast Trend (2024-2032)
6.2.6.4.3 Break Up by Country
6.2.6.4.3.1 China
6.2.6.4.3.2 Japan
6.2.6.4.3.3 India
6.2.6.4.3.4 ASEAN
6.2.6.4.3.5 Australia
6.2.6.4.3.6 Others
6.2.6.5 Latin America
6.2.6.5.1 Historical Trend (2017-2023)
6.2.6.5.2 Forecast Trend (2024-2032)
6.2.6.5.3 Break Up by Country
6.2.6.5.3.1 Brazil
6.2.6.5.3.2 Argentina
6.2.6.5.3.3 Mexico
6.2.6.5.3.4 Others
6.2.6.6 Middle East and Africa
6.2.6.6.1 Historical Trend (2017-2023)
6.2.6.6.2 Forecast Trend (2024-2032)
6.2.6.6.3 Break Up by Country
6.2.6.6.3.1 Saudi Arabia
6.2.6.6.3.2 United Arab Emirates
6.2.6.6.3.3 Nigeria
6.2.6.6.3.4 South Africa
6.2.6.6.3.5 Others
7 Current Scenario Evaluation and Regulatory Framework
7.1 Emerging Therapies and Clinical Trials Synopsis
7.2 Patent Landscape
7.2.1 Patent Overview
7.2.1.1 Patent Status and Expiry
7.2.1.2 Timelines from Drug Development to Commercial Launch
7.2.1.3 New Drug Application
7.2.1.3.1 Documentation and Approval Process
7.3 Cost of Treatment
7.4 Regulatory Framework
7.4.1 Regulatory Overview
7.4.1.1 US FDA
7.4.1.2 EU EMA
7.4.1.3 INDIA CDSCO
7.4.1.4 JAPAN PMDA
7.4.1.5 Others
8 Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Global Bladder Cancer Treatment Market Dynamics
9.1 Market Drivers and Constraints
9.2 SWOT Analysis
9.3 Porter’s Five Forces Model
9.4 Key Demand Indicators
9.5 Key Price Indicators
9.6 Industry Events, Initiatives and Trends
9.7 Value Chain Analysis
10 Supplier Landscape
10.1 AstraZeneca Plc.
10.1.1 Company Overview
10.1.2 Product Portfolio
10.1.3 Demographic Reach and Achievements
10.1.4 Mergers and Acquisitions
10.1.5 Certifications
10.2 Bristol-Myers Squibb Co.
10.2.1 Company Overview
10.2.2 Product Portfolio
10.2.3 Demographic Reach and Achievements
10.2.4 Mergers and Acquisitions
10.2.5 Certifications
10.3 Celgene Corporation
10.3.1 Company Overview
10.3.2 Product Portfolio
10.3.3 Demographic Reach and Achievements
10.3.4 Mergers and Acquisitions
10.3.5 Certifications
10.4 Pfizer Inc.
10.4.1 Company Overview
10.4.2 Product Portfolio
10.4.3 Demographic Reach and Achievements
10.4.4 Mergers and Acquisitions
10.4.5 Certifications
10.5 GlaxoSmithKline Plc.
10.5.1 Company Overview
10.5.2 Product Portfolio
10.5.3 Demographic Reach and Achievements
10.5.4 Mergers and Acquisitions
10.5.5 Certifications
10.6 Eli Lilly and Company
10.6.1 Company Overview
10.6.2 Product Portfolio
10.6.3 Demographic Reach and Achievements
10.6.4 Mergers and Acquisitions
10.6.5 Certifications
10.7 F. Hoffmann-La Roche AG
10.7.1 Company Overview
10.7.2 Product Portfolio
10.7.3 Demographic Reach and Achievements
10.7.4 Mergers and Acquisitions
10.7.5 Certifications
10.8 Novartis International AG
10.8.1 Company Overview
10.8.2 Product Portfolio
10.8.3 Demographic Reach and Achievements
10.8.4 Mergers and Acquisitions
10.8.5 Certifications
10.9 Sanofi S.A.
10.9.1 Company Overview
10.9.2 Product Portfolio
10.9.3 Demographic Reach and Achievements
10.9.4 Mergers and Acquisitions
10.9.5 Certifications
10.10 Merck & Co. Inc.
10.10.1 Company Overview
10.10.2 Product Portfolio
10.10.3 Demographic Reach and Achievements
10.10.4 Mergers and Acquisitions
10.10.5 Certifications
10.11 Genetech Inc.
10.11.1 Company Overview
10.11.2 Product Portfolio
10.11.3 Demographic Reach and Achievements
10.11.4 Mergers and Acquisitions
10.11.5 Certifications
10.12 Johnson & Johnson Services, Inc
10.12.1 Company Overview
10.12.2 Product Portfolio
10.12.3 Demographic Reach and Achievements
10.12.4 Mergers and Acquisitions
10.12.5 Certifications
10.13 Viventia Bio Inc.
10.13.1 Company Overview
10.13.2 Product Portfolio
10.13.3 Demographic Reach and Achievements
10.13.4 Mergers and Acquisitions
10.13.5 Certifications
10.14 Spectrum Pharmaceuticals, Inc.
10.14.1 Company Overview
10.14.2 Product Portfolio
10.14.3 Demographic Reach and Achievements
10.14.4 Mergers and Acquisitions
10.14.5 Certifications
10.15 Herantis Pharma Plc.
10.15.1 Company Overview
10.15.2 Product Portfolio
10.15.3 Demographic Reach and Achievements
10.15.4 Mergers and Acquisitions
10.15.5 Certifications
10.16 Taris Biomedical LLC
10.16.1 Company Overview
10.16.2 Product Portfolio
10.16.3 Demographic Reach and Achievements
10.16.4 Mergers and Acquisitions
10.16.5 Certifications
10.17 Prometic Life Sciences Inc.
10.17.1 Company Overview
10.17.2 Product Portfolio
10.17.3 Demographic Reach and Achievements
10.17.4 Mergers and Acquisitions
10.17.5 Certifications
11 Recommendations and Discussion
12 Global Bladder Cancer Treatment Drugs Distribution Model (Additional Insight)
12.1 Overview
12.2 Potential Distributors
12.3 Key Parameters for Distribution Partner Assessment
13 Payment Methods (Additional Insight)
13.1 Government Funded
13.2 Private Insurance
13.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
The market is likely to grow at a CAGR of 9.31% during the forecast period of 2024-2032.
The market attained a value of USD 4.03 billion in 2023.
The market is expected to reach a value of USD 8.98 billion by 2032.
The factors stimulating the development of the market are bladder infections, genetic alteration, smoking, and chemical exposure, and a rise in R&D expenditure in biopharmaceutical companies.
Lack of awareness and rising treatment cost are the suspected reasons for hindering the growth of this market.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific, with North America accounting for the largest share in the market.
The top companies involved are AstraZeneca Plc., Bristol-Myers Squibb Co., Celgene Corporation, Pfizer Inc., GlaxoSmithKline Plc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Novartis International AG, Sanofi S.A., Merck & Co. Inc., Genetech Inc., Johnson & Johnson Services, Inc, Viventia Bio Inc., Spectrum Pharmaceuticals, Inc., Herantis Pharma Plc., Prometic Life Sciences Inc., and Taris Biomedical LLC.
The detection of non-muscle invasive bladder cancer can be done through blood tests, urine cytology, cystoscopy, or computerised tomography.
Datasheet
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.